



Myriad Genetics has seen the positive impact of change as we continue to fulfill our mission of health and well-being for all. Our organization continues to evolve to meet the opportunities ahead. Today, we are announcing the following updates:

**Mark Verratti** has been promoted to Chief Commercial Officer. Mark will continue to oversee the Mental Health business unit along with this new expanded role. We also will be hiring a General Manager for Mental Health. Mark had over 20 years of success leading large commercial organizations in the pharmaceutical and medical device industries before joining the GeneSight team in 2016. In his time on the GeneSight business, Mark has focused on transforming the commercial model to better serve current and new customers by complementing a talented field team with focused marketing lead generation and growing an inside sales team. As a result, the Mental Health business unit saw strong growth in 2021. Since joining Myriad, Mark has demonstrated strong commercial, sales, marketing and leadership capabilities as well as the ability to effectively engage and inspire teammates across the enterprise. In his new role, Mark will accelerate the work of the enterprise growth team to enhance our commercial and marketing capabilities, build the Myriad Genetics brand, gain new customer insights, and enhance demand generation.

Mark succeeds **Eric Santa** who has served as Chief Growth Officer. Eric is pursuing a new opportunity as president of a start-up company. I want to thank Eric for his contributions to advancing our growth. We wish him all the best.

In addition to Mark's appointment, I am pleased to announce that **Dale Muzzey** has been promoted to Chief Scientific Officer (CSO). Dale has served as our interim CSO since the beginning of this year, bringing deep scientific expertise and leadership skills to the role. During that time, he has continued to apply meaningful innovation to elevate our products to their full potential and deliver new solutions and services. Dale is a Harvard trained biochemist and biophysicist who has been with us for eight years, making significant contributions to current prenatal products such as Foresight and Prequel. As his role has expanded, he has been instrumental in the development of upcoming new products such as the FirstGene Comprehensive Prenatal Screen launching next year. Dale is also advancing future offerings that will bring our expertise in genetic testing for cancer applications into the liquid biopsy and MRD (Measurable Residual Disease) spaces.

We are fortunate to have a deep bench of talent, including leaders like Mark and Dale, as we accelerate our transformation and growth plans in 2022 and beyond.

Paul J. Diaz  
President and CEO  
Myriad Genetics